athenahealth Company Profile (NASDAQ:ATHN)

athenahealth trades on the NASDAQ under the ticker symbol "ATHN."

athenahealth, Inc. (NASDAQ:ATHN) released its earnings results on Thursday, July, 20th. The company reported $0.51 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.39 by $0.12. The company earned $301.10 million during the quarter, compared to analyst estimates of $298.68 million. athenahealth had a return on equity of 6.91% and a net margin of 2.80%. athenahealth's quarterly revenue was up 15.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.34 earnings per share. View athenahealth's Earnings History.

athenahealth is scheduled to release their next quarterly earnings announcement on Wednesday, October, 18th 2017. View Earnings Estimates for athenahealth.

23 brokerages have issued 1 year price targets for athenahealth's shares. Their forecasts range from $88.00 to $190.00. On average, they expect athenahealth's share price to reach $146.70 in the next year. View Analyst Ratings for athenahealth.

Here are some recent quotes from research analysts about athenahealth stock:

• 1. Cantor Fitzgerald analysts commented, "It is difficult to predict what the ultimate outcome will be given the Elliott stake. Over the years, ATHN has typically invested for longer-term growth, which has often resulted in inconsistent quarterly performance. After a bumpy roll-out of the streamlined platform last year, we believe performance has improved. Also, the company’s investment in the small hospital market is moving along better than we originally expected. We maintain our view that the company can help physician offices transition to value-based reimbursement and increase its population health offerings. It remains to be seen if athena can enhance the functionality of its hospital offering to move into larger hospitals. Still, athena continues to have a significant presence in the ambulatory market, and it should be able to better leverage its capabilities over time. Praxify Techologies acquisition reflects another long-term investment. On June 7, ATHN announced that it acquired privately-held Praxify Technologies for $63 million in cash. We characterize this acquisition as a technology acquisition which should help the company add app-layer technology to its ambulatory and inpatient products. We assume the acquisition will be dilutive in the near term but help the company’s long-term product performance. Basis for higher price target. With the filing by Elliott, we increased our DCF-based price target to $140." (6/13/2017)
• 2. Piper Jaffray Companies analysts commented, "We have updated our model and estimates to reflect the new company presentation. We have slightly lowered our PT to $160 from $162 to reflect our revised estimates. Despite this we remain confident in the company's FY17 outlook, and would be buying shares at current market valuation. Reiterate OW, PT $160." (2/7/2017)
• 3. Stifel Nicolaus analysts commented, "ATHN reported 4Q EPS after the close 2/2/17 with a call at 8am ET this morning. Revenue ($288.2mn) was 5% ($17mn) below consensus and guidance, while EPS of $0.62 exceeded consensus ($0.51). Management reiterated 2017 revenue, bookings and adjusted operating income guidance; however, with the revenue miss revenue growth must reaccelerate more than previously expected and margins must improve less." (2/6/2017)
• 4. According to Zacks Investment Research, "We believe that athenahealth’s strong product portfolio, expanding physician base and unique business model will continue to drive the top line. The recognition of athenahealth as an Electronic Health Record (EHR) usability leader is also a significant positive, in our opinion. However, the company's second quarter 2016 results disappointed us, as it missed the Zacks Consenus Estimates on both the lines. The company's guidance also failed to impress us. We believe lack of enterprise-sized deals, winding up of government funded stimulus and increasing competition in the HCIT market are major headwinds, at least in the near term." (8/4/2016)

Some companies that are related to athenahealth include Veeva Systems (VEEV), Cotiviti Holdings (COTV), HealthEquity (HQY), Allscripts Healthcare Solutions (MDRX), Evolent Health (EVH), Omnicell (OMCL), Emis Group Plc (EMIS), Castlight Health, inc. (CSLT), NantHealth (NH), Craneware plc (CRW), Simulations Plus (SLP), Tabula Rasa Healthcare (TRHC), Fluidigm Corporation (FLDM), Medical Transcription Billing, Corp. (MTBC), Constellation Healthcare Tech (CHT) and Press Ganey Holdings (PGND).

athenahealth's management team includes the folowing people:

• Jonathan S. Bush, Chairman of the Board, President, Chief Executive Officer
• Karl Stubelis, Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer
• Stephen N. Kahane M.D., Executive Vice President ; President - Client Organisation
• Prakash Khot, Senior Vice President, Chief Technology Officer
• Timothy O'Brien, Senior Vice President, Chief Marketing Officer
• Dan Haley, Senior Vice President, General Counsel, Secretary
• Kyle Armbrester, Senior Vice President, Chief Product Officer
• Brandon H. Hull, Lead Independent Director
• Thomas J. Szkutak, Director
• Amy Abernethy M.D. Ph.D., Independent Director

athenahealth's stock is owned by many different of retail and institutional investors. Top institutional investors include JANUS HENDERSON GROUP PLC (14.60%), Riverbridge Partners LLC (2.60%), Sumitomo Mitsui Asset Management Company LTD (1.09%), ELLIOTT ASSOCIATES, L.P. (1.00%), Barton Investment Management (0.60%) and Peregrine Capital Management LLC (0.35%). Company insiders that own athenahealth stock include Amy Abernethy, Bradford Kyle Armbrester, Brandon H Hull, Daniel P Haley, Ed Park, John A Kane, Jonathan Bush, Jonathan D Porter, Karl Stubelis, Kristi Ann Matus, Robert Cosinuke, Stephen N Kahane and Timothy John O'brien. View Institutional Ownership Trends for athenahealth.

athenahealth's stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Gagnon Securities LLC, Peregrine Capital Management LLC, Riverbridge Partners LLC, Gagnon Advisors LLC, Rockefeller Financial Services Inc., US Bancorp DE and Clear Harbor Asset Management LLC. Company insiders that have sold athenahealth stock in the last year include Amy Abernethy, Bradford Kyle Armbrester, Brandon H Hull, Daniel P Haley, Ed Park, John A Kane, Jonathan Bush, Jonathan D Porter and Karl Stubelis. View Insider Buying and Selling for athenahealth.

athenahealth's stock was purchased by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Asset Management Company LTD, Barton Investment Management, Huntington National Bank, CrestPoint Capital Management LLC, Aperio Group LLC and Cribstone Capital Management LLC. View Insider Buying and Selling for athenahealth.

Shares of athenahealth can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of athenahealth stock can currently be purchased for approximately $152.42.